STUDY: Liquid Biopsy Could Guide Prostate Cancer Therapy, Complement PET Imaging
By: Julie Poucher Harbin, Senior Writer, DCI
Prostate-specific membrane antigen (PSMA) expression on circulating tumor cells (CTCs) in men with metastatic castrate-resistant prostate cancer (mCRPC) is known to increase upon disease progression during treatment with abiraterone or enzalutamide. PSMA-targeted radioligand therapy has dramatically improved clinical outcomes in these cases.
"Recent prospective data from the PROPHECY trial set the stage for a liquid biopsy of CTCs to assess PSMA expression that could complement PSMA PET imaging and identify men more or less likely to benefit from drugs that target PSMA," says Andrew Armstrong, MD, MSc, PROPHECY PI and senior author of a new paper published this month in Clinical Cancer Research.
PROPHECY was funded in 2014 with a Prostate Cancer Foundation-Movember Challenge Award, and has resulted in eight publications so far, with more to come.
